New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - lanreotide acetate 149.4mg equivalent to lanreotide 120 mg - solution for injection - 120 mg - active: lanreotide acetate 149.4mg equivalent to lanreotide 120 mg excipient: glacial acetic acid water for injection - treatment of acromegaly when circulating levels of gh and igf-1 remain abnormal after surgery and/or radiotherapy, or in patients who are dopamine agonist treatment refractory. treatment of symptoms of carcinoid syndrome associated with carcinoid tumours. the treatment of well or moderately differentiated gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - lanreotide acetate 77.9mg equivalent to lanreotide 60 mg - solution for injection - 60 mg - active: lanreotide acetate 77.9mg equivalent to lanreotide 60 mg excipient: glacial acetic acid water for injection - treatment of acromegaly when circulating levels of gh and igf-1 remain abnormal after surgery and/or radiotherapy, or in patients who are dopamine agonist treatment refractory. treatment of symptoms of carcinoid syndrome associated with carcinoid tumours. the treatment of well or moderately differentiated gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - lanreotide acetate 113.6mg equivalent to lanreotide 90 mg - solution for injection - 90 mg - active: lanreotide acetate 113.6mg equivalent to lanreotide 90 mg excipient: glacial acetic acid water for injection - treatment of acromegaly when circulating levels of gh and igf-1 remain abnormal after surgery and/or radiotherapy, or in patients who are dopamine agonist treatment refractory. treatment of symptoms of carcinoid syndrome associated with carcinoid tumours. the treatment of well or moderately differentiated gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.

Singapore - English - HSA (Health Sciences Authority)

ipsen pharma singapore pte. ltd. - lanreotide acetate 149.4mg eqv lanreotide - injection, solution - 120 mg - lanreotide acetate 149.4mg eqv lanreotide 120 mg

Singapore - English - HSA (Health Sciences Authority)

ipsen pharma singapore pte. ltd. - lanreotide acetate 77.9mg eqv lanreotide - injection, solution - 60 mg - lanreotide acetate 77.9mg eqv lanreotide 60 mg

Singapore - English - HSA (Health Sciences Authority)

ipsen pharma singapore pte. ltd. - lanreotide acetate 113.6mg eqv lanreotide - injection, solution - 90 mg - lanreotide acetate 113.6mg eqv lanreotide 90 mg

Ireland - English - HPRA (Health Products Regulatory Authority)

ipsen pharmaceuticals limited - lanreotide acetate - solution for injection in pre-filled syringe - 90 milligram(s) - somatostatin and analogues; lanreotide

Ireland - English - HPRA (Health Products Regulatory Authority)

ipsen pharmaceuticals limited - lanreotide acetate - solution for injection in pre-filled syringe - 120 milligram(s) - somatostatin and analogues; lanreotide

Ireland - English - HPRA (Health Products Regulatory Authority)

ipsen pharmaceuticals limited - lanreotide acetate - solution for injection in pre-filled syringe - 60 milligram(s) - somatostatin and analogues; lanreotide

Ireland - English - HPRA (Health Products Regulatory Authority)

ipsen pharmaceuticals limited - lanreotide - powder and solvent for suspension for injection - 30 milligram(s) - somatostatin and analogues; lanreotide